NDAORAL-21TABLETPriority Review
Approved
Mar 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO/OVRAL is an oral contraceptive combining ethinyl estradiol (estrogen) and norgestrel (progestin) in a 21-day tablet formulation. It prevents pregnancy through ovulation suppression and cervical mucus thickening. This product represents a foundational hormonal contraceptive option in women's health.
LOE Approaching
Product is in late-stage lifecycle with approaching loss-of-exclusivity; expect reduced team investment and consolidation of brand support functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Positions linked to LO/OVRAL are focused on defensive strategies, regulatory maintenance, and supply chain management rather than growth or innovation. Career progression on this product is limited; professionals typically use such roles as stepping stones to newer products or transition into generic administration and compliance functions.
Regulatory Affairs Specialist
Worked on LO/OVRAL at Cadence Neuroscience? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.